ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. As necessary, this list will be updated with the posting of errata reports on www.usp.org/USPNF/newOfficialText. This information will also be available as a cumulative table in future *Supplements*, and will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

Page Number	Title	Section	Description
USP32–NF27			
40	*USP Reference Standards* ⟨11⟩	USP Open Ring Aztreonam RS	Change: "$C_{18}H_{19}N_5O_9S_2$ 453.46" to: $C_{13}H_{19}N_5O_9S_2$ 453.45
1772	*Dibasic Calcium Phosphate Tablets*	*Assay*	Line 10: Change "Proceed as directed in the *Assay* under *Dibasic Calcium Phosphate*, beginning with "With constant stirring"." to: With constant stirring, add, in the order named, 0.5 mL of triethanolamine, 300 mg of hydroxy naphthol blue, and, from a 50-mL buret, about 23 mL of 0.05 M edetate disodium VS. Add sodium hydroxide solution (45 in 100) until the initial red color changes to clear blue. Continue to add it dropwise until the color changes to violet, and add an additional 0.5 mL. The pH is 12.3–12.5. Continue the titration dropwise with the 0.05 M edetate disodium VS to the appearance of a clear blue endpoint that persists for NLT 60 s.
2034	*Cupric Sulfate*	*Limit of sodium*	Delete second *Limit test* table.
1030	*Glucosamine Tablets*	*Assay*	Line 2: Change "*Phosphate buffer*, *Mobile phase*, *Standard preparation*, and *Chromatographic system*—Proceed as directed in the *Assay* under *Glucosamine Hydrochloride*. *Assay preparation*—Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the finely powdered material, equivalent to about 80 mg of glucosamine, to a 100-mL volumetric flask, add 60 mL of water, and sonicate for 10 minutes. Shake by mechanical means for 15 minutes. Dilute with water to volume, and mix." to: *Diluent*, *Phosphate buffer*, *Mobile phase*, *Standard preparation*, and *Chromatographic system*—Proceed as directed in the *Assay* under *Glucosamine Hydrochloride*. *Assay preparation*—Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the finely powdered material, equivalent to about 312 mg of glucosamine, to a 100-mL volumetric flask, add 60 mL of *Diluent*, and sonicate for 10 minutes. Shake by mechanical means for 15 minutes. Dilute with *Diluent* to volume, and mix.
1280	*Methyl Alcohol*	*Assay*	Line 2 under *Standard preparation*: Change "accurately measured" to: accurately weighed
			Line 1 under *Assay preparation*: Change "accurately measured" to: accurately weighed
3330	*Potassium Acetate*	*Limit of Sodium*	Line 13 under *Procedure*: Change "*CD*/10,000*W*" to: *CD*/(10,000*W*)

Page Number	Title	Section	Description
First Supplement to USP32–NF27			
4028	*Albuterol Sulfate*	*Assay*	Line 4 under *Chromatographic system*: Change "*Standard preparation*" to: *Resolution solution*
4017	*Glucosamine Sulfate Potassium Chloride*	*Assay*	Line 5 under *Procedure*: Change "(605.52/431.26)(10,000*C*/*W*)(r_U/r_S)" to: (605.52/431.26)(5000*C*/*W*)(r_U/r_S)
4017	*Glucosamine Sulfate Sodium Chloride*	*Assay*	Line 5 under *Procedure*: Change "10,000(573.31/431.26)(*C*/*W*)(r_U/r_S)" to: 5000(573.31/431.26)(*C*/*W*)(r_U/r_S)
USP33–NF28 Reissue			
R-456	*Amlodipine Besylate Tablets*	IMPURITIES Organic Impurities	Line 18 under *Analysis*: Change "impurity" to: unspecified degradation product
			Line 25 under *Analysis*: Change "USP Amlodipine Besylate RS" to: Amlodipine
First Supplement to USP33–NF28 Reissue			
R-925	*Levalbuterol Hydrochloride*	Assay	Line 1 under *Solution A*: Change "1 mg/mL" to: 1 in 1000 solution
R-927	*Levetiracetam*	Assay	Line 2 under *Procedure*: Change "*Buffer*: 0.26 g/L of monobasic potassium phosphate in water. Adjust with 2% aqueous potassium hydroxide (w/v) to a pH of 5.5." to: *Buffer*: 2.7 g/L of monobasic potassium phosphate in water. Adjust with 2% aqueous potassium hydroxide (w/v) to a pH of 5.5.
R-861	*Sorbitol Sorbitan Solution*	Assay	Line 3 under *Procedure*: Change "*System suitability solution*: 10 mg/mL of sorbitol, 4 mg/mL of 1,4-sorbitan, 4 mg/mL of isosorbide, and 1 mg/mL of mannitol *Standard solution*: 10 mg/mL of USP Sorbitol RS and 4 mg/mL of USP 1,4-Sorbitan RS" to: *System suitability solution*: 10 mg/g of sorbitol, 4 mg/g of 1,4-sorbitan, 4 mg/g of isosorbide, and 1 mg/g of mannitol in water *Standard solution*: 10 mg/g of USP Sorbitol RS and 4 mg/g of USP 1,4-Sorbitan RS in water
			Lines 12 and 14 under *Analysis*: Change "mg/mL" to: mg/g

Page Number	Title	Section	Description
R-994	*Valacyclovir Hydrochloride*	IMPURITIES Organic Impurities Impurity Table 2	Line 1 under footnote [b]: Change "[b] 2-Amino-1,9-dihydro-6*H*-purin-6-one (guanine). [c] 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6*H*-purin-6-one (acyclovir). [d] 2-[(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)methoxy]ethyl L-alaninate. and [h] 2-[[(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)methyoxy]ethyl isoleucinate. [i] 2-[(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)methoxy]ethyl *N*-formyl-L-valinate. [j] 2-[[6-Oxo-2-[[[(6-oxo-6,9-dihydro-1*H*-purin-2-yl)amino]methyl]amino]-1,6-dihydro-9*H*-purin-9-yl]methoxy]ethyl L-valinate. [k] 2,2′-[Methylenebis[imino(6-oxo-1,6-dihydro-9*H*-purine-9,2-diyl)methylene-oxy]]diethyl di(L-valinate." to: [b] 2-Amino-1*H*-purin-6(9*H*)-one (guanine). [c] 9-[(2-Hydroxyethoxy)methyl]guanine (acyclovir). [d] 9-[(2-Hydroxyethoxy)methyl]guanine L-alaninate. and [h] 9-[(2-Hydroxyethoxy)methyl]guanine L-isoleucinate. [i] 9-[(2-Hydroxyethoxy)methyl]guanine *N*-formyl-L-valinate. [j] [N^2-(Guanine-N^2-yl)methyl]-9-[(2-hydroxyethoxy)methyl]guanine L-valinate. [k] 2,2′-[Methylenebis[imino(6-oxo-1,6-dihydro-9*H*-purine-9,2-diyl)methylene-oxy]]diethyl di(L-valinate).
		IMPURITIES Organic Impurities Impurity Table 3	Line 1 under footnote [a]: Change "[a] 2-Amino-1,9-dihydro-6*H*-purin-6-one (guanine). [b] 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6*H*-purin-6-one (acyclovir)." to: [a] 2-Amino-1*H*-purin-6(9*H*)-one (guanine). [b] 9-[(2-Hydroxyethoxy)methyl]guanine (acyclovir).
I-23, I-26, I-52	*Index*		In the *Index* under *General Chapters*: Change "⟨467⟩ *Residual Solvents*, 163" to: ⟨467⟩ *Residual Solvents*, 163, R-622
			In the *Index* under *General Chapters*: Change "*Residual Solvents* ⟨467⟩, 163" to: *Residual Solvents* ⟨467⟩, 163, R-622
			In the *Index* under *R*: Change "*Residual Solvents* ⟨467⟩, 163" to: *Residual Solvents* ⟨467⟩, 163, R-622
Second Supplement to USP33–NF28 Reissue			
R-1074	⟨670⟩ *Containers–Auxiliary Components*	*Polyester Pharmaceutical Coil*	Line 3 under *Identification* test *A*: Change "400 cm^{-1} (2.5 to 25 μm)" to: 650 cm^{-1} (2.5 to 15 μm)
			Line 2 under *Loss on Drying* ⟨731⟩: Change "NMT 0.5%" to: NMT 1.0%
R-1485	*Vancomycin Hydrochloride*	IMPURITIES Organic Impurities Procedure: Limit of Monodechlorovancomycin	Line 1 under *Mobile phase*: Change "Dissolve 2.2 g of 1-heptanesulfonic acid" to: Dissolve 2.2 g of 1-heptanesulfonic acid sodium salt

Page Number	Title	Section	Description
I-24, I-27, and I-54	*Index*		In the *Index* under *General Chapters*: Change "⟨467⟩ *Residual Solvents*, 163" to: ⟨467⟩ *Residual Solvents*, 163, R-622
			In the *Index* under *General Chapters*: Change "*Residual Solvents* ⟨467⟩, 163" to: *Residual Solvents* ⟨467⟩, 163, R-622
			In the *Index* under *R*: Change "*Residual Solvents* ⟨467⟩, 163" to: *Residual Solvents* ⟨467⟩, 163, R-622
USP34–NF29			
1976	*Aztreonam Injection*	*USP Reference standards* ⟨11⟩	Line 2 under *USP Open Ring Aztreonam RS*: Change "$C_{18}H_{19}N_5O_9S_2$ 453.46" to: $C_{13}H_{19}N_5O_9S_2$ 453.45
1976	*Aztreonam for Injection*	*USP Reference standards* ⟨11⟩	Line 2 under *USP Open Ring Aztreonam RS*: Change "$C_{18}H_{19}N_5O_9S_2$ 453.46" to: $C_{13}H_{19}N_5O_9S_2$ 453.45
2093	*Bupropion Hydrochloride Extended-Release Tablets*	*USP Reference standards* ⟨11⟩	Line 2 under *USP Bupropion Hydrochloride Related Compound F RS*: Change "1-(3-Chlorophenyl)-1-hydroxy-2-propanone. $C_9H_9O_2$ 184.62" to: 1-(3-Chlorophenyl)-1-hydroxy-2-propanone. $C_9H_9O_2Cl$ 184.62
2150	*Capreomycin for Injection*	SPECIFIC TESTS Capreomycin 1 Content	Line 6 under *Analysis*: Change "Calculate the percentage of capreomycin 1 in the capreomycin sulfate taken:" to: Calculate the percentage of capreomycin 1 in the portion of Capreomycin for Injection taken:
2746	*Estradiol Vaginal Inserts*	*Identification* test *A, Thin-Layer Identification Test* ⟨201⟩	Line 2: Change "[NOTE—When a concentration range is given...]" to: [NOTE—When two different concentrations are given...]
		Assay	Line 1 under *Procedure*: Change "[NOTE—When a concentration range is given...]" to: [NOTE—When two different concentrations are given...]
2896	*Fluticasone Propionate*	*USP Reference standards* ⟨11⟩	Line 1 under *USP Fluticasone Propionate RS*: Change all instances of "*B*" in the chemical name to: *β*
			Line 1 under *USP Fluticasone Propionate System Suitability Mixture RS*: Change all instances of "*B*" in the chemical names for *Fluticasone propionate related compound A, B, C, D, and E* to: *β*
3325	*Lithium Carbonate Tablets*	PERFORMANCE TESTS Dissolution ⟨711⟩	Line 3 under *Analysis*: Change "Determine the amount of Li_2CO_3 dissolved:" to: Determine the percentage of Li_2CO_3 dissolved:
3727	*Ondansetron Tablets*	*Identification* test *A, Infrared Absorption* ⟨197K⟩	Line 4 under *Sample*: Change "45-µm pore size" to: 0.45-µm pore size
4002	*Prednisolone Sodium Phosphate*	*Related compounds*	Line 2 under *Standard solution*: Change "prednisolone sodium phosphate" to: USP Prednisolone Sodium Phosphate RS
			Line 2 under *Test solution*: Change "prednisolone sodium phosphate" to: Prednisolone Sodium Phosphate

Page Number	Title	Section	Description
4219	*Sertraline Tablets*	IMPURITIES Organic Impurities	Line 10 under *Analysis*: Change "C_S = concentration of USP Sertraline RS in the *Standard solution* (mg/mL)" to: C_S = concentration of USP Sertraline Hydrochloride RS in the *Standard solution* (mg/mL)
4246	*Sodium Fluoride Gel*	*Identification*	Line 1 under *Sample solution*: Change "*Sample solution*: Amount of Gel, equivalent to 500 mg of fluoride ion" to: *Sample*: Amount of Gel, equivalent to 500 mg of fluoride ion
			Line 1 under *Analysis*: Change "*Sample solution*" to: *Sample*
First Supplement to USP34–NF29			
5047	*Tetracycline Hydrochloride Capsules*	*Assay*	Line 1 under *System suitability solution*: Change "*System suitability solution*: 100 µg/mL of tetracycline hydrochloride and 25 µg/mL of USP 4-Epianhydrotetracycline Hydrochloride RS" to: *System suitability solution*: 100 µg/mL of tetracycline hydrochloride and 25 µg/mL of USP 4-Epianhydrotetracycline Hydrochloride RS in *Diluent*
			Line 8 under *Chromatographic system*: Add "Injection volume: 20 µL"
Revision Bulletin, October 1, 2010			
1	*Nifedipine Extended-Release Tablets*	*Dissolution* ⟨711⟩, *Test 6*	Table 8 is missing.